0001178913-24-001224.txt : 20240405 0001178913-24-001224.hdr.sgml : 20240405 20240405130521 ACCESSION NUMBER: 0001178913-24-001224 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240405 FILED AS OF DATE: 20240405 DATE AS OF CHANGE: 20240405 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRINITY BIOTECH PLC CENTRAL INDEX KEY: 0000888721 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22320 FILM NUMBER: 24825831 BUSINESS ADDRESS: STREET 1: IDA BUSINESS PARK, BRAY, CO WICKLOW STREET 2: IRELAND CITY: DUBLIN IRELAND STATE: L2 ZIP: 18 BUSINESS PHONE: 01135312955111 MAIL ADDRESS: STREET 1: 3 ROCK ROAD STREET 2: SANDYFORD INDUSTRIAL ESTATES CITY: DUBLIN IRELAND STATE: L2 ZIP: 18 6-K 1 zk2431251.htm 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

F O R M 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2024

TRINITY BIOTECH PLC
(Name of Registrant)

IDA Business Park
Bray, Co. Wicklow, Ireland
 (Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒      Form 40-F ☐      

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):          

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):          

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐      No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-               


 EXPLANATORY NOTE

On April 4, 2023, Trinity Biotech plc. issued a press release announcing its fourth quarter and fiscal year 2023 financial results & business updates. A copy of the press release is furnished herewith as Exhibit 99.1.


EXHIBIT INDEX

Exhibit
 
Description
 
 
 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
TRINITY BIOTECH PLC
  
   
Trinity Biotech plc
  
   
(Registrant)
  
       
 
By:
/s/ Des Fitzgerald
  
   
Des Fitzgerald
  
   
Interim Chief Financial Officer
  

Date: April 5, 2024
 EX-99.1 2 exhibit_99-1.htm EXHIBIT 99.1
Exhibit 99.1

Contact:
Trinity Biotech plc
Des Fitzgerald
(353)-1-2769800
LifeSci Partners, LLC
Eric Ribner
(1)-646-751-4363
E-mail: investorrelations@trinitybiotech.com
               
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023
Financial Results & Business Updates

DUBLIN, Ireland (April 4, 2024)…. Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.

Business Updates

Comprehensive Transformation Plan

At the Emerging Growth Investor Conference on March 7, 2024, our new management team announced a comprehensive transformation plan to deliver a step change in the financial performance of our existing business.

Our transformation plan for the existing business has several key components that we believe are rapidly achievable, in most cases by mid-2025:

 •
We are reducing complexity and cost by consolidating our main manufacturing operations into a considerably smaller number of sites and also moving to an outsourced model for a significant amount of our less complex manufacturing activities.

o
As part of this initiative, we are today announcing that we intend to cease manufacturing at our Kansas City manufacturing plant which currently serves our Haemoglobin business.  We expect to have fully executed this change by the end of 2024 and expect this will deliver significant annualised savings.

•
We are also significantly reducing the cost of goods of many of our products by changing suppliers and negotiating new deals with existing suppliers.

o
This is an area we have already successfully executed on a number of cost saving initiatives, which we expect will deliver multi-million-dollar annualised savings.

•
We are simplifying our internal operations, and optimising our business support function locations:

o
Today we are announcing an initiative to move significant aspects of our business support functions to a lower cost and centralised location.  We plan to complete this activity by Q4, 2024 and it is expected to deliver significant reductions to our existing SG&A costs, plus provide an efficient scalable business support platform to facilitate efficient growth in our wearable biosensor business.

Financial Guidance

The Company is targeting approximately $20 million of Annualised Run-Rate EBITDASO1 on annualised run-rate revenues of approximately $75 million by Q2, 2025. This outlook is predicated solely on growth from the existing businesses including haemoglobin testing and HIV, and planned improvements to operating margins, with no contribution from the recently acquired biosensor business.

Biosensor Technology Acquisition and Progress Updates

In January 2024, the Company announced the acquisition of the biosensor assets of Waveform Technologies Inc. (“Waveform”) for $12.5 million in cash and 1.8 million American Depositary Shares (“ADS”) plus contingent consideration. We plan to build a global business in wearable biosensors and are taking the first steps by using this acquired technology to develop a next generation version of a continuous glucose monitor (“CGM”). We believe that our CGM will have a number of game changing benefits compared to the leading CGMs on the market today, specifically with respect to affordability, sustainability and enhanced data capture.

Since the acquisition, we have been building out our new biosensor team to augment the Waveform team members we hired, and have made a number of senior appointments across a number of areas including programme management, R&D, regulatory & quality and operations.  These new team members come from leading medical device and diabetes management companies such as Phillips, Johnson & Johnson and Lifescan.

Our team is progressing our plans across a number of areas including:


 •
Planning and executing sensor design improvements based on the existing CGM product design, with the assistance of external technical & design consultants.

•
Initiating enhanced data analysis on Waveform’s large existing data bank of clinical trial results.

•
Progressing discussions and agreements with potential commercial partners for the launch of CGM products.

•
Establishing a scientific and user advisory group for CGM to support our product development efforts and ensuring that user needs continue to be at the forefront of our efforts.

We will keep investors appraised on progress in this business as we advance our plans forward.

Execution On Key Initiatives

 •
Optimization of our existing Diabetes business:

o
Launch of the Improved Column System: Our programme to develop an improved, backward compatible Diabetes HbA1c column system is now completed. The results of this development programme have exceeded expectations, with our new column system now delivering up to 4 times the number of injections compared to the existing product. As planned, we are now executing on the commercial launch of these new products.

o
In-house manufacturing process: Our revised in-house manufacturing process of our key Diabetes HbA1c consumable began in Q4, 2023 as planned, and in Q1, 2024 we ceased to order any further product from our outsourced supplier.

o
We remain on track to deliver approximately $4 million of annualised recurring cost savings from this and our ongoing Diabetes business supply chain optimisation initiatives, based on expected production volumes, and we believe that these changes will allow us to deliver an increasingly cost competitive Diabetes HbA1c solution, putting us in a stronger position to grow market share over time.

•
TrinScreen HIV update:

o
Earlier this week we received a purchase order for an additional 2 million TrinScreen HIV tests for the Kenya market and expect to deliver these in Q2, 2024.

o
Additionally, in Q1, 2024 we successfully scaled manufacturing of our new rapid HIV screening test, TrinScreen HIV and have manufactured all 2.5 million tests from the initial Kenya purchase order.

o
The ability to deliver such a significant increase in production capacity was an important demonstration to our stakeholders of our execution capabilities and our commitment to the new HIV testing algorithm adopted by the Kenyan Ministry of Health that established TrinScreen HIV as the screening test under World Health Organisation guidelines.

o
The Kenyan HIV screening programme is one of the largest in Africa, with up to an estimated 10 million screening tests annually.

1 Earnings before interest, tax, depreciation, amortisation, share based payments – also excludes impairment charges and one-off items

Fourth Quarter Results
 
The results of the Fitzgerald Industries life sciences supply business, which was sold as of April 27, 2023, have been reported separately as discontinued operations in the Consolidated Income Statements for all periods presented. The assets and liabilities attributable to Fitzgerald Industries have been removed from our Consolidated Balance Sheet as of December 31, 2023.
 
Total revenues for Q4, 2023 were $13.4m which compares to $15.7m in Q4, 2022, a decrease of 14.6% and which were broken down as follows:
 
 
2023
Quarter 4
2022
Quarter 4
Decrease
 
US$’000
US$’000
%
Clinical laboratory
11,279
13,050
13.6%
Point-of-Care
2,149
2,675
19.7%
Total
13,428
15,725
14.6%

Clinical laboratory revenues for the quarter were $11.3m, compared to $13.1m in Q4, 2022, representing a decrease of $1.8m or 13.6%. This decrease in clinical laboratory revenues was driven by lower revenues for haemoglobins, autoimmune and COVID-19 related products. Haemoglobins revenues in Q4, 2023 were $1.0 million lower than in Q4, 2022. As announced in our business update two months ago, our haemoglobins revenues were reduced in Q4, 2023 by the deferral of shipments of products at sub-optimal pricing as we renegotiated contract terms with a key customer in line with the new management team’s focus on profitability. As of Q1, 2024, these revised terms have been agreed upon.
 
Autoimmune lab services and product revenue in Q4, 2023 were $0.6 million lower than in Q4 2022 primarily because we ceased transplant testing activity at our New York laboratory in early 2023. Lastly, there was a reduction of $0.2 million in revenues from our COVID-19 VTM products. Partly offsetting these decreases was an increase in revenues for clinical chemistry products of $0.2m in Q4, 2023 compared to Q4, 2022.
 
Point-of-Care revenues for Q4, 2023 decreased from $2.7m to $2.2m when compared to Q4, 2022, a decrease of 19.7%.  Lower revenues from our HIV confirmatory test, Uni-Gold caused the decrease which was attributed to the irregular quarter on quarter ordering patterns that characterise the HIV testing market in Africa. This decrease was partly offset by $0.4m of revenues for our new HIV screening test, TrinScreen HIV, following our first shipments to Kenya in December 2023.
 
Gross Profit
 
In Q4, 2023, gross profit was $4.6m, equating to a gross margin of 34.0%. In Q4, 2022, gross profit amounted to $5.4m equating to a gross margin of 34.2%.
 
Other operating income
 
Other operating income decreased from $0.3m in Q4, 2022 to zero in Q4, 2023. Other operating income in Q4, 2022 was comprised of government grants in relation to R&D activities and there were no equivalent grants in Q4, 2023.
 
R&D and SG&A
 
Research and development expenses were $1.1m in Q4, 2023, which is broadly flat compared to Q4, 2022.
 
Selling, general and administrative expenses (“SG&A”) were $6.9m in Q4, 2023, compared to $9.7m in Q4, 2022. The reduction in SG&A expenses is mainly due to lower share-based payments expenses, which decreased by $2.3m in Q4, 2023 compared to Q4, 2022. This decrease is primarily due to the reversal of the cumulative share-based payment expense for unvested options related to the former CEO due to his resignation in Q4, 2023. Included within our SG&A spend this quarter were professional advisory and consulting fees of $1.8m, which we would consider to be higher than normal.  The main driver of this were costs associated with the acquisition of the biosensor assets of Waveform (which closed in January 2024). These expenses related to the Waveform acquisition are non-recurring in nature, and we expect our go forward quarterly non-product development professional advisory, audit and consulting fees to be approximately a quarter of what was incurred in Q4, 2023, unless we engage in additional transactions.
 
Impairment Charges
 
The Company recognised an impairment charge of $0.3m in Q4, 2023, compared to an impairment charge of $3.0m in Q4, 2022. The charge in Q4, 2023 was driven by an impairment loss in two cash generating units, namely Trinity Biotech Do Brasil ($0.2m) and Immco Diagnostics Inc. (“Immco”) ($0.1m).
 
Operating Loss
 
Operating loss decreased from $8.2m in Q4, 2022, to $3.8m in Q4, 2023 and was mainly attributable to lower impairment charges and SG&A expenses in Q4, 2023.
 
Financial income and expenses
 
Financial income for Q4, 2023 was $0.6m compared to $0.1m for Q4, 2022. In both quarters the financial income related to a fair value adjustment for the derivative liability related to warrants granted to the Group’s principal lender, Perceptive Advisors. The liability reduced by $0.6m in Q4, 2023 mainly due to a decrease in the price per ADS, leading to a gain of that amount.
 
Financial expenses in Q4, 2023 were $2.3m compared to $2.4m in Q4, 2022, a decrease of $0.1m. The decrease is mainly due to lower cash interest expense for the senior secured term loan due to the reduced principal amount outstanding during Q4 2023, compared to the equivalent quarter in 2022 partly offset by a higher interest rate in Q4, 2023.
 
Other Items
 
The loss after tax for continuing operations for the quarter was $5.5m in comparison to a loss of $10.4m for the equivalent period last year. This decrease is primarily due to lower impairment charges and SG&A expenses and higher financial income, offset by lower gross profit and other operating income.
 
Loss before interest, tax, depreciation, amortisation, share based payments credit and impairment charges for Q4, 2023 (Adjusted EBITDASO) was $4.0m.  This is made up as follows:
 
 
US$’M
Operating loss
(3.8)
Depreciation & Amortisation
0.5
Impairment charges
0.3
Adjusted EBITDA
(3.0)
Credit for share based payments
(1.0)
Adjusted EBITDASO
(4.0)

 
Liquidity
 
The Group’s cash balance decreased from $6.3m at the end of Q3, 2023 to $3.7m at the end of Q4, 2023, a decrease of $2.6m. Cash generated from operations for Q4, 2023 was $0.3m, a decrease of $2.0m compared to Q4, 2022.  During Q4, 2023 the Company had capital expenditure cash outflows of $0.9m (Q4, 2022: $1.1m) and payments for property leases of $0.6m (Q4, 2022: $0.6m). Interest payments in the quarter were $1.2m (Q4, 2022: $1.2m).
 
In January 2024, the Company entered into an amended credit agreement (the “Amended Term Loan”) with its existing main lender, Perceptive Advisors. Under the Amended Term Loan, an additional $22 million of funding was made available to the Company, with $12.5 million being used to acquire the Waveform assets. The remaining $9.5 million is available for general corporate purposes including for the further development of the CGM and biosensor technologies. In addition, the Amended Term Loan provides for additional liquidity of up to $6.5 million, that may be drawn down by the Company between April and December 2024, and can be used for general corporate purposes, thereby providing further liquidity to fund the development of the CGM and biosensor technologies. The Amended Term Loan also immediately reduced the annual rate of interest on the loan by 2.5% to 8.75% (the “Base Rate”) plus the greater of (a) Term Secured Overnight Financing Rate (SOFR) or (b) 4.0% per annum, and allows for a further 2.5% reduction in the Base Rate to 6.25% once the outstanding principal under the Amended Term Loan falls below $35 million. Additionally, the Amended Term Loan reduced the early repayment penalty from a range of 8% to 7% to 4.0% to 3.5%, dependent on timing of early repayment, and also reduced the revenue covenants. The Amended Term Loan matures in January 2026.
 
Fiscal Year 2023 Results
 
Total revenues for continuing operations for fiscal year 2023 were $56.8m compared to $62.5m in 2022, a decrease of 9.1% year on year and were broken down as follows:
 
 
Full Year
2023
Full Year
2022
Decrease
 
US$’000
US$’000
%
Clinical laboratory
47,741
53,308
10.4%
Point-of-Care
9,091
9,213
1.3%
Total
56,832
62,521
9.1%

Clinical laboratory product revenues decreased by $5.6m from $53.3m for the year ended December 31, 2022 to $47.7m for year ended December 31, 2023, which represents a decrease of 10.4%. This decrease in clinical laboratory revenues was driven by i) lower revenues for our COVID-19 related products of $1.8m year on year as COVID-19 testing programs scaled down, ii) lower autoimmune lab services revenue of $1.8m,  primarily due to the loss of our transplant testing service contract with a local healthcare provider which ended in Q1, 2023 and iii) declines in our haemoglobin business, with revenues 8% lower year on year due to a) the predicted decrease in revenues for our legacy haemoglobinopathies product, the Ultra II instrument, and b) due to the deferral of shipments in Q4, 2023 of products at sub-optimal pricing as we renegotiated contract terms with a key customer in line with the new management team’s focus on profitability. As of Q1, 2024, these revised terms have been agreed upon.
 
Point-of-Care revenues for the year 2023 were broadly flat (-1.3%) compared to 2022. Included in our HIV point-of-care revenues is $0.4m in relation to our TrinScreen HIV test, which commenced its first shipments in the month of December 2023.
 
Gross profit for the year ended December 31, 2023 amounted to $19.5m, representing a gross margin of 34.2%. This is 6.6% higher than fiscal year 2022. The increase in margin percentage year on year was primarily due to an inventory obsolescence charge of $4.7million in Q3, 2022. In 2023, we also had some inventory obsolescence charges in relation to our VTM products and the Tri-stat instrument but these charges were significantly lower than the amount recorded in Q3, 2022.
 
Other operating income decreased from $0.3m for the year ended December 31, 2022 to $0.1m for the year ended December 31, 2023. The income for 2023 relates to a transition services agreement with the acquirers of Fitzgerald Industries. The income for 2022 was comprised of government grants in relation to R&D activities and there were no equivalent grants in 2023.
 
R&D and SG&A
 
Research and development expenses increased from $4.1 million to $4.4 million when compared to the year ended December 31, 2022, an increase of 5.8% mainly due to lower capitalisation of product payroll costs into product development intangible assets.
 
Selling, General and Administrative (“SG&A”) expenses increased by $4.2m to $31.2m when compared to the year ended December 31, 2022, representing an increase of 15.5%. A significant element of the $4.2m increase relates to i) an increase in technical advisory, legal and professional fees of $1.6 million, primarily due to  the acquisition of the biosensor assets of Waveform (which closed in January 2024) together with other corporate development and corporate finance activities as we continue to assess strategic opportunities and balance sheet optimization initiatives and ii) an increase of $1.5m in foreign exchange losses largely relating to the accounting revaluation of euro-denominated lease liabilities for right-of-use assets.
 
Impairment Charges
 
Impairment charges increased from $5.8m for the year ended December 31, 2022 to $11.1m for the year ended December 31, 2023. The impairment charges for the year ended December 31, 2023 relate to Immco ($10.8m) and Trinity Biotech Do Brasil ($0.3m). The impairment in Immco was driven by i) lost revenues as a local healthcare provider transferred its requirement for transplant testing services to a different service provider, ii) the expected level of laboratory services revenue arising from its partnership with imaware, Inc (“imaware”) have not materialised and iii) a full impairment of the financial assets associated with the Group’s investment in imaware.
 
Operating Loss
 
Operating loss for the year ended December 31, 2023 was $27.0m, compared to an operating loss of $19.3m in the year ended December 31, 2022. The higher loss was mainly attributable to decreased revenues, lower other operating income, higher impairment charges and higher indirect costs, partly offset by a higher gross margin.
 
Financial expenses
 
Financial expenses in the year ended December 31, 2023 were $11.1m compared to $24.7m in the year ended December 31, 2022, a decrease of $13.6m, broken down as follows:
 
 
Full Year 2023
Full Year 2022
 
US$’M
US$’M
Interest on senior secured term loan
8.4
       9.8
Interest on convertible note
1.1
       0.7
Penalty for early partial settlement of term loan
0.9
       3.5
Lease interest
0.6
       0.7
Loss on disposal of exchangeable notes
0.0
       9.7
Interest on exchangeable notes
0.0
       0.4
Other non-cash financial expense
0.0
       0.1
 Total
      11.1
     24.7

Note: table above contains rounded numbers
 
The year-on-year decrease is mainly due to two material expenses incurred in 2022, which were a loss of $9.7m on the disposal of the exchangeable notes and an early repayment penalty of $3.5m, compared to $0.9m in 2023.
 
Interest on the senior secured term loan, comprising cash and non-cash interest, decreased from $9.8m in 2022 to $8.4m for 2023 as the principal amount outstanding was lower across the 2023 financial year, although this was partly offset by the impact of higher prevailing interest rates during 2023. Interest on the convertible note, comprising cash and non-cash interest, increased from $0.7m in 2022 to $1.1m in 2023 due to the full year effect (the convertible note was issued in Q2, 2022). An early repayment penalty of $0.9m was incurred in Q2, 2023 because of an early partial settlement of the term loan of $10.1m. Interest on exchangeable notes decreased from $0.4m in 2022 to $8,000 in 2023 because 99.7% of the exchangeable notes were retired during Q1, 2022.
 
Other Items
 
Financial income for the year ended December 31, 2023 was $1.2m compared to $0.3m for the year ended December 31, 2022. In both years the financial income related to a fair value adjustment for the derivative liability related to warrants granted to the Group’s principal lender.
 
The loss before tax for continuing operations for the year ended December 31, 2023 was $36.9m, in comparison to $43.8m for the year ended December 31, 2022.
 
Profit for the period from discontinued operations totalled $12.9 million, largely attributable to the gain of $12.7m on the divesture of Fitzgerald Industries. The gain consisted of proceeds of approximately $30.0m offset by transaction costs of $1.3m with net assets eliminated on disposal of $16.0 million.
 
Loss before interest, tax, depreciation, amortisation, share based payments and impairment charges for 2023 (Adjusted EBITDASO) was $12.1m.  This is made up as follows:
 
 
$m
Operating loss
(27.0)
Depreciation & Amortisation
1.7
Impairment charges
11.1
   
Adjusted EBITDA
(14.2)
Share option expense
2.1
   
Adjusted EBITDASO
(12.1)

Non-GAAP Measures
 
The attached summary unaudited financial statements were prepared in accordance with International Financial Reporting Standards (IFRS). To supplement the consolidated financial statements presented in accordance with IFRS, the Company presents non-IFRS presentations of, Adjusted EBITDA and Adjusted EBITDASO. The adjustments to the Company's IFRS results are made with the intent of providing both management and investors a more complete understanding of the Company's underlying operational results, trends, and performance. Non-IFRS financial measures mainly exclude, if and when applicable, the effect of share-based compensation, significant excess and obsolescence charges related to inventory, depreciation, amortization and impairment charges.
 
Adjusted EBITDA and Adjusted EBITDASO are presented to evaluate the Company's financial and operating results on a consistent basis from period to period. The Company also believes that these measures, when viewed in combination with the Company's financial results prepared in accordance with IFRS, provides useful information to investors to evaluate ongoing operating results and trends. Adjusted EBITDA and adjusted EBITDASO, however, should not be considered as an alternative to operating income or net income for the period and may not be indicative of the historic operating results of the Company; nor is it meant to be predictive of potential future results. Adjusted EBITDA and adjusted EBITDASO are not measures of financial performance under IFRS and may not be comparable to other similarly titled measures for other companies. Reconciliation between the Company's operating profit/(loss) and Adjusted EBITDA and Adjusted EBITDASO are presented.
 
Forward-Looking Statements
 
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterised by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this presentation may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on our purchase of the assets of Waveform, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2022 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.
 
About Trinity Biotech
 
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors.  The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company's website: www.trinitybiotech.com.
 
.
Trinity Biotech plc
Consolidated Income Statements

(US$000’s except share data)
  
Three Months Ended
December 31, 2023
(unaudited)
    
Three Months Ended
December 31, 2022
(unaudited)
    
Twelve Months Ended
December 31, 2023
(unaudited)
    
Twelve Months Ended
December 31, 2022
  
                         
Revenues
    
13,428
      
15,725
      
56,832
      
62,521
  
                                 
Cost of sales
    
(8,861
)
    
(10,350
)
    
(37,382
)
    
(45,253
)
                                 
Gross profit
    
4,567
      
5,375
      
19,450
      
17,268
  
Gross margin %
    
34.0
%
    
34.2
%
    
34.2
%
    
27.6
%
                                 
Other operating income
    
-
      
341
      
141
      
343
  
                                 
Research & development expenses
    
(1,117
)
    
(1,166
)
    
(4,379
)
    
(4,138
)
Selling, general and administrative expenses
    
(6,939
)
    
(9,675
)
    
(31,152
)
    
(26,983
)
Impairment charges
    
(290
)
    
(3,032
)
    
(11,105
)
    
(5,839
)
                                 
Operating Loss
    
(3,779
)
    
(8,157
)
    
(27,045
)
    
(19,349
)
                                 
Financial income
    
611
      
112
      
1,171
      
303
  
Financial expenses
    
(2,337
)
    
(2,384
)
    
(11,053
)
    
(24,734
)
Net financing expense
    
(1,726
)
    
(2,272
)
    
(9,882
)
    
(24,431
)
                                 
Loss before tax
    
(5,505
)
    
(10,429
)
    
(36,927
)
    
(43,780
)
                                 
Income tax credit
    
3
      
13
      
59
      
194
  
Loss for the period on continuing operations
    
(5,502
)
    
(10,416
)
    
(36,868
)
    
(43,586
)
                                 
Profit for the period on discontinued operations
    
-
      
336
      
12,850
      
2,577
  
Loss for the period (all attributable to owners of the parent)
    
(5,502
)
    
(10,080
)
    
(24,018
)
    
(41,009
)
                                 
Loss per ADS (US cents)
    
(71.8
)
    
(132.3
)
    
(313.8
)
    
(607.8
)
                                 
Diluted loss per ADS (US cents)
    
(71.8
)
    
(132.3
)
    
(313.8
)
    
(607.8
)
                                 
Weighted average no. of ADSs used in computing basic earnings per ADS*
    
7,665,514
      
7,621,514
      
7,654,970
      
6,746,966
  
                                 
Weighted average no. of ADSs used in computing diluted earnings per ADS*
    
7,665,514
      
7,621,514
      
7,654,970
      
6,746,966
  

*As of February 23, 2024, Trinity Biotech changed the ratio of its American Depositary Shares (“ADS”) from one (1) ADS representing four (4) ‘A’ ordinary shares to one (1) ADS representing twenty (20) ‘A’ ordinary shares. The above loss per ADS calculations reflects this change.

Trinity Biotech plc
Consolidated Balance Sheets

   
December 31,
2023
US$ ‘000
(unaudited)
    
September 30,
2023
US$ ‘000
(unaudited)
    
December 31,
2022
US$ ‘000
  
ASSETS
                  
Non-current assets
                  
Property, plant and equipment
    
1,892
      
1,804
      
5,682
  
Goodwill and intangible assets
    
16,270
      
16,164
      
35,269
  
Deferred tax assets
    
1,975
      
1,507
      
4,218
  
Derivative financial asset
    
178
      
196
      
128
  
Other assets
    
79
      
98
      
139
  
Total non-current assets
    
20,394
      
19,769
      
45,436
  
                         
Current assets
                        
Inventories
    
19,933
      
20,880
      
22,503
  
Trade and other receivables
    
13,901
      
15,095
      
15,753
  
Income tax receivable
    
1,516
      
1,592
      
1,834
  
Cash, cash equivalents and deposits
    
3,691
      
6,261
      
6,578
  
Total current assets
    
39,041
      
43,828
      
46,668
  
                         
TOTAL ASSETS
    
59,435
      
63,597
      
92,104
  
                         
EQUITY AND LIABILITIES
                        
Equity attributable to the equity holders of the parent
                        
Share capital
    
1,972
      
1,972
      
1,963
  
Share premium
    
46,619
      
46,619
      
46,458
  
Treasury shares
    
(24,922
)
    
(24,922
)
    
(24,922
)
Accumulated deficit
    
(48,644
)
    
(42,135
)
    
(26,695
)
Translation reserve
    
(5,706
)
    
(5,753
)
    
(5,775
)
Equity component of convertible note
    
6,709
      
6,709
      
6,709
  
Other reserves
    
23
      
23
      
86
  
Total deficit
    
(23,949
)
    
(17,487
)
    
(2,176
)
                         
Current liabilities
                        
Income tax payable
    
279
      
252
      
28
  
Trade and other payables
    
14,496
      
12,226
      
17,051
  
Exchangeable senior note payable
    
210
      
210
      
210
  
Provisions
    
50
      
50
      
50
  
Total current liabilities
    
15,035
      
12,738
      
17,339
  
                         
Non-current liabilities
                        
Senior secured term loan
    
40,109
      
39,947
      
44,301
  
Derivative financial liability
    
526
      
1,138
      
1,569
  
Convertible note
    
14,542
      
14,337
      
13,746
  
Other payables
    
10,872
      
10,921
      
12,267
  
Deferred tax liabilities
    
2,300
      
2,003
      
5,058
  
Total non-current liabilities
    
68,349
      
68,346
      
76,941
  
                         
TOTAL LIABILITIES
    
83,384
      
81,084
      
94,280
  
                         
TOTAL EQUITY AND LIABILITIES
    
59,435
      
63,597
      
92,104
  


Trinity Biotech plc
Consolidated Statements of Cash Flows

 
  
Three
Months
Ended
December 31, 2023
US$ ‘000
(unaudited)
    
Three Months Ended
December 31, 2022
US$ ‘000
(unaudited)
   
Twelve Months Ended
December 31, 2023
US$ ‘000
(unaudited)
    
Twelve Months Ended
December 31, 2022
US$ ‘000
 
Cash flows from operating activities
                        
Loss for the period
    
(5,502
)
    
(10,080
)
    
(24,018
)
    
(41,009
)
Adjustments to reconcile loss to cash generated by/(used in) operating activities:
                                
Depreciation
    
2
      
453
      
831
      
1,410
  
Amortisation
    
460
      
215
      
946
      
923
  
Income tax credit
    
(3
)
    
(16
)
    
(59
)
    
(192
)
Financial income
    
(611
)
    
(112
)
    
(1,171
)
    
(303
)
Financial expense
    
2,337
      
2,395
      
11,053
      
24,744
  
Share-based payments
    
(1,009
)
    
1,318
      
2,069
      
1,756
  
Foreign exchange gains on operating cash flows
    
385
      
(91
)
    
238
      
(76
)
Impairment charge
    
290
      
3,032
      
11,105
      
5,839
  
Gain on sale of business
    
-
      
-
      
(12,718
)
    
-
  
Other non-cash items
    
2,602
      
3,061
      
2,548
      
7,662
  
 
                                
Operating cash inflows/(outflows) before changes in working capital
    
(1,049
)
    
175
      
(9,176
)
    
754
  
Net movement on working capital
    
1,359
      
2,112
      
(2,693
)
    
(1,662
)
 
                                
Cash generated by/(used in) operations
    
310
      
2,287
      
(11,869
)
    
(908
)
Interest received
    
-
      
-
      
-
      
2
  
Income taxes (paid)/received
    
(65
)
    
(12
)
    
312
      
(15
)
 
                                
Net cash generated by/(used in) operating activities
    
245
      
2,275
      
(11,557
)
    
(921
)
 
                                
Cash flows from investing activities
                                
Payments to acquire intangible assets
    
(641
)
    
(663
)
    
(1,901
)
    
(4,876
)
Acquisition of property, plant and equipment
    
(250
)
    
(475
)
    
(803
)
    
(1,101
)
Payments to acquire financial asset
    
-
      
-
      
(700
)
    
-
  
Proceeds from sale of business (net of transaction costs)
    
-
      
-
      
28,160
      
-
  
 
                                
Net cash generated by/(used in) investing activities
    
(891
)
    
(1,138
)
    
24,756
      
(5,977
)
 
                                
Cash flows from financing activities
                                
Issue of ordinary share capital including share premium (net of issuance costs)
    
-
      
(130
)
    
-
      
25,336
  
Proceeds from shares to be issued
            
63
      
-
      
63
  
Net proceeds from new senior secured term loan
    
-
      
-
      
5,000
      
80,015
  
Proceeds for convertible note issued
    
-
      
-
      
-
      
20,000
  
Expenses paid in connection with debt financing
    
-
      
-
      
(147
)
    
(2,356
)
Purchase of exchangeable notes
    
-
      
-
      
-
      
(86,730
)
Repayment of senior secured term loan
    
-
      
-
      
(10,050
)
    
(34,500
)
Penalty for early settlement of term loan
    
-
      
-
      
(905
)
    
(3,450
)
Repayment of other loan
    
-
      
(23
)
    
-
      
(23
)
Interest paid on senior secured term loan
    
(1,129
)
    
(1,103
)
    
(7,314
)
    
(6,424
)
Interest paid on convertible note
    
(75
)
    
(75
)
    
(300
)
    
(199
)
Interest paid on exchangeable notes
    
(4
)
    
-
      
(8
)
    
(1,293
)
Payment of lease liabilities
    
(558
)
    
(577
)
    
(2,318
)
    
(2,761
)
 
                                
Net cash used in financing activities
    
(1,766
)
    
(1,845
)
    
(16,042
)
    
(12,322
)
 
                                
Decrease in cash and cash equivalents
    
(2,412
)
    
(708
)
    
(2,843
)
    
(19,220
)
Effects of exchange rate movements on cash held
    
(158
)
    
32
      
(44
)
    
(112
)
Cash and cash equivalents at beginning of period
    
6,261
      
7,254
      
6,578
      
25,910
  
 
                                
Cash and cash equivalents at end of period
    
3,691
      
6,578
      
3,691
      
6,578
  

GRAPHIC 3 image1.jpg begin 644 image1.jpg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end